BSx BSX ボストン・サイエンティフィック

 BSXのチャート


 BSXの企業情報

symbol BSx
会社名 Boston Scientific Corp. (BSX ボストン・サイエンティフィック)
分野(sector)   
産業(industry)   
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 ボストン・サイエンティフィック(Boston Scientific Corporation)はインターベンション医療専門分野に使用される医療機器の開発・製造・販売に従事する会社である。同社はインターベンション心臓病学、心臓リズム管理、内視鏡検査、末梢介入、泌尿器と骨盤の健康、神経調節、電気生理学という7つの事業によって製品を提供する。同社は3つの事業区分により構成される。心臓血管事業は介入的心臓病学と周辺介入事業を含む。リズム管理事業は心臓リズム管理と電気生理学事業を含む。MedSurg事業は内視鏡検査、泌尿器科と骨盤の健康検査、神経変性治療を含む。インターベンショナル・カーディオロジー製品はバルーン・カテーテル、回転アテローム切除システム、ガイド・ワイヤー、ガイド・カテーテル、塞栓防止装置、経皮的冠動脈形成術(PTCA)に使用される診断用カテーテルを含む。  ボストン・サイエンティフィックは米国の医療機器メ―カ―。主要製品は不整脈の治療用の植込み型除細動器とペ―スメ―カ―、ステント、バル―ンカテ―テルなどを提供。呼吸器と消化器分野に内視鏡、泌尿器・婦人科用の尿路結石症、子宮出血治療用製品、疼痛治療用の脊髄電気装置や血管内超音波装置も扱う。事業は米国、欧州、中東、アフリカ、日本で展開。  Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, The company advances science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.
本社所在地 508 683-4000
代表者氏名 Michael F. Mahoney
代表者役職名 Chairman of the Board President Chief Executive Officer
電話番号 +1 508-683-4000
設立年月日 1979年
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 32000人
url www.bostonscientific.com
nasdaq_url
adr_tso
EBITDA EBITDA(百万ドル) 2634.00000
終値(lastsale)
時価総額(marketcap)
時価総額 時価総額(百万ドル) 53367.38000
売上高 売上高(百万ドル) 9823.00000
企業価値(EV) 企業価値(EV)(百万ドル) 60277.38000
当期純利益 当期純利益(百万ドル) 1604.00000
決算概要 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Boston Scientific Corporation revenues increased 9% to $9.82B. Net income applicable to common stockholders excluding extraordinary items increased 66% to $1.6B. Revenues reflect Rhythm and Neuro segment increase of 40% to $3.04B Cardiovascular segment increase of 8% to $3.78B United States segment increase of 7% to $5.54B.

 BSXのテクニカル分析


 BSXのニュース

   IHI: A Standout Performer With Equally Strong Future Growth Prospects  2022/03/05 05:42:51 Kwhen Finance
   Boston Scientific finance subsidiary prices €3B of senior notes (NYSE:BSX)  2022/03/04 11:46:44 Seeking Alpha
American Medical Systems Europe, a wholly-owned finance subsidiary of Boston Scientific (BSX), has priced a public offering of €3B of senior notes.The offering comprises €1B…
   Boston Scientific begins tender offer for up to $2.5B debt securities  2022/03/02 10:32:53 Seeking Alpha
Sundry Photography/iStock Editorial via Getty Images Boston Scientific (NYSE:BSX) began a cash tender offer for up to $2.5B principal amount of certain outstanding senior notes.Holders of…
   Hopeful Golden Cross Forms On Boston Scientific''s Chart  2022/03/01 14:51:27 Benzinga
If history is any guide, there may be good fortune ahead for shares of Boston Scientific (NYSE: BSX ). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock. What To Know: Many traders use moving average crossover systems to make their decisions. When a shorter-term average price crosses above a longer-term average price, it could mean the stock is trending higher. If the short-term average price crosses below the long-term … Full story available on Benzinga.com
   Global Drug-Device Combinations Markets Report 2022: Data from 2020, Estimates from 2021, & CAGR Projections Through 2026 - ResearchAndMarkets.com  2022/03/01 11:13:00 Kwhen Finance
   Ureteroscope Market Anticipated to Witness a Significant CAGR of 5.47% by 2026, Estimates DelveInsight  2022/02/08 18:00:00 Benzinga
Las Vegas, USA, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Ureteroscope Market Anticipated to Witness a Significant CAGR of 5.47% by 2026, Estimates DelveInsight The growing demand for Ureteroscope Market is primarily attributed to the growing prevalence of urolithiasis or nephrolithiasis accompanied by the rising burden of obesity which is a risk factor for the development of kidney stones, and the entrance of key pharma players such as Olympus, Stryker, Boston Scientific Corporation, Richard Wolf GmbH, KARL STORZ in the Ureteroscope Market DelveInsight''s Ureteroscope Market Insights and Forecast report provides the current and forecast Ureteroscope, upcoming innovation in the devices, individual market shares of the devices, challenges, drivers and barriers, market trends, and key competitors in the Ureteroscope Market scenario. Some of the essential takeaways from the Ureteroscope Market report: According to DelveInsight analysis, North America is expected to dominate the overall Ureteroscope Market during the forecasted period.
   What 5 Analyst Ratings Have To Say About Boston Scientific  2022/02/03 15:33:34 Benzinga
Over the past 3 months, 5 analysts have published their opinion on Boston Scientific (NYSE: BSX ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company''s business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 1 0 0 Last 30D 1 1 1 0 0 1M Ago 0 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 0 0 0 0 In the last 3 months, 5 analysts have offered 12-month price targets for Boston Scientific. The company has an average price target of $49.8 with a high of $53.00 and a low of Full story available on Benzinga.com
   Did Hedge Funds Catch A Break With Boston Scientific Corporation (BSX)?  2022/02/03 00:31:06 Insider Monkey
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
   Boston Scientific (BSX) Q4 2021 Earnings Call Transcript  2022/02/02 22:30:45 The Motley Fool
BSX earnings call for the period ending December 31, 2021.
   Boston Scientific Corporation 2022 Q4 - Results - Earnings Call Presentation  2022/02/02 18:18:09 Seeking Alpha
   RBC startet Boston Scientific  2021/12/09 21:33:59 GodmodeTrader
RBC startet Boston Scientific mit Outperform. Kursziel 51 Dollar.
   Relyea Zuckerberg Hanson LLC Sells 783 Shares of Boston Scientific Co. (NYSE:BSX)  2021/12/09 15:12:43 Transcript Daily
Relyea Zuckerberg Hanson LLC cut its holdings in Boston Scientific Co. (NYSE:BSX) by 3.6% during the 3rd quarter, Holdings Channel reports. The fund owned 21,198 shares of the medical equipment providers stock after selling 783 shares during the period. Relyea Zuckerberg Hanson LLCs holdings in Boston Scientific were worth $920,000 as of its most recent []
   Congestive Heart Failure Treatment Devices Market is Thriving USD 14,828.3 million with Top Vendors Abiomed, Inc., Berlin Heart GmbH,Boston Scientific Corporation  2021/12/09 13:05:01 OpenPR
Congestive Heart Failure (CHF) may be a state that has associate adverse impact on the pumping potency of the internal organ muscles. It characterizes the buildup of fluid round the heart resulting in inefficient pumping. Congestive Heart Failure (CHF) Treatment Devices
   Interventional Oncology Devices Market Trend, Demands, Size, Share and Top Companies AngioDynamics, BD, Boston Scientific, Eckert & Ziegler BEBIG GmbH, HealthTronics  2021/12/09 11:07:21 OpenPR
The Interventional Oncology Devices Market report makes available the basic information about industry, definition, classification, application, industry chain structure, industry overview, and international market analysis. As per this report, the market is expected to grow at a substantial Compound Annual
   Pain Management Devices Market worth $3.3 billion by 2026 - Leading Key Players are Medtronic PLC (Ireland), Boston Scientific (US), Abbott (US)  2021/12/09 09:31:10 OpenPR
According to the new market research report "Pain Management Devices Market by Type (Neurostimulation, SCS, TENS, RF Ablation, Infusion Pumps), Application (Neuropathy, Cancer, Facial, MSK, Migraine), Mode of Purchase (OTC, Prescription-based) & Region (NA, Europe, APAC) - Global Forecasts to

 関連キーワード  (先端医療機器_テクノロジ― 米国株 BSX ボストン・サイエンティフィック BSX )

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)